ClinicalTrials.gg
RecruitingNCT04899154MEDIBIOTE 3Updated Sep 25, 2025

Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy

An interventional study of stool sampling and stool sampling in Spondyloarthritis, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Hôpital Européen Marseille · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 10 months after the study started (first participant enrolled Jul 2019, registered May 2021).
  • Started Jul 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Spondylarthritis with a site in France — 17 open to participants now, 19 under way, none of them phase 3. Spondylarthritis · France.

Planned enrollment
25th of 36
80 · median 108
Started
2019
with 7 others
No phase
31 of 73
8 open now
Primary completion
2026-05
later than 4 of 18 live
Registered
51st of 73
by date

Among the 73 studies in Spondylarthritis with a site in France, this one is the 25th largest by planned enrollment of the 36 interventional ones that give a count, is one of 8 that started in 2019, is one of 31 with no phase, reaches primary completion later than 4 of the 18 other live ones, and was the 51st registered.

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

Browse Spondylarthritis studies →

Open to participants now

17 of the 73 studies in Spondylarthritis with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Spondylarthritis with a site in France, or all of them as a file.
02

Study summary

Spondyloarthritis (SpA) is a group of inflammatory rheumatic disorders that mainly manifested by inflammatory pain of the spine, pelvis and sometimes limbs. Classically, SpA has been classified into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), inflammatory bowel disease (IBD)-associated.

Several studies have shown specific changes in the gut microbiota during SpA. A recent, uncontrolled study suggested that the therapeutic response to anti-TNFα (Tumor Necrosis Factor) therapy could be predicted by analysis of the gut microbiota.

The purpose of the study MEDIBIOTE 3 is to confirm that in SpA, the composition of the intestinal microbiota at the initiation of treatment is predictive of the response to treatment with biotherapy (anti-TNFα / anti-IL17).

03

Conditions studied

  • Spondyloarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patient with spondyloarthritis:

  • Diagnosed for spondyloarthritis or pure axial or axial type psoriatic rheumatism according to Assessment of Spondyloarthritis International Society (ASAS) criteria.
  • Requiring treatment with anti-TNFα or anti- IL-17 according to the treatment recommendations of the French Society of Rheumatology (SFR)
  • patient not previously treated with biotherapy
  • Aged ≥ 18 years
  • Having given free and informed written consent
  • Being affiliated to the center national security system social

For control Subject:

  • Healthy volunteers without diagnosis of spondyloarthritis or any other chronic disease.
  • Aged ≥ 18 years
  • Having given free and informed written consent
  • Being affiliated with or benefiting from a social security scheme.

Exclusion criteria

Exclusion Criteria:

  • Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within one month before stool sampling.
  • Association with another chronic pathology
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Patients with spondyloarthritis (Spa)

    Other: stool sampling

  • Experimental
    Healthy subjects

    Other: stool sampling

Interventions

  • Otherstool sampling

    Participants will provide two stool samples: one collected the day of inclusion and a second, four months later after anti-TNF α or anti- IL-17 (interleukin-17) treatment initiation.

  • Otherstool sampling

    Participants will provide one stool sample at inclusion

06

What researchers measure

Primary outcomes

  1. Variability in the qualitative and quantitative composition of intestinal microbiota in patients responding to biotherapy compared to the group of non-responding patients

    Time frame: 18 Months

Secondary outcomes

  1. Differences on intestinal microbiota composition (qualitative and quantitative) of patients with Spa versus healthy controls.

    Time frame: 18 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for May 2026, 81 months after the start.

Of 44 non-industry interventional studies with no phase under Spondylarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 77. This study's planned 81 months is above that.

Counting every sponsor, half of 46 studies reached it within 30 months; a quarter within 16 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 24, 2021
StartActual
Jul 16, 2019
Primary completionEst.
May 15, 2026
CompletionEst.
May 15, 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04899154
Lead sponsor
Hôpital Européen Marseille
Responsible party
Sponsor
First posted
May 24, 2021
Start date
Jul 16, 2019
Primary completion
May 15, 2026 (estimated)
Completion
May 15, 2026 (estimated)
Last update
Sep 25, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion